US1101221083 - Common Stock - After market: 72.3 -0.15 (-0.21%)
NYSE:BMY (1/27/2023, 7:04:01 PM)-0.54 (-0.74%)
|GICS Sector||Health Care|
|Earnings (Last)||10-25 2022-10-25/amc||Earnings (Next)||02-02 2023-02-02|
|Ins Owners||0.05%||Inst Owners||77.31%|
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. The company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. The company also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
BRISTOL-MYERS SQUIBB CO
430 E. 29Th Street, 14 Floor
New York City NEW YORK 10016
CEO: Giovanni Caforio
These companies are established leaders in their respective fields.
The EU drug regulator said a group of experts backed expanding the marketing nod for anemia therapy Reblozyl which Bristol Myers (MBY) markets with Merck (MRK). Read the full story here.
These companies have the therapies to boost revenue for a decade.
Bristol Myers Squibb (BMY) announced Thursday that a Phase 1/2 trial for CAR T cell therapy Breyanzi met main goal in adults with certain type of leukemia. Read the full story here.
Here you can normally see the latest stock twits on BMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.